🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

Recruitingn/aAges 0 Years - 25 YearsAllLille University
NCT06924463 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 0 and 25 years at the time of initial diagnosis * Diagnosis of rhabdomyosarcoma confirmed histologically * Care at the Oscar Lambret Center between January 2005 and November 2024 * No objection to the re-use of data and biological samples collected as part of care for research activities. Exclusion Criteria: * Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret; * Patient under guardianship or trusteeship.
💊

What it tests

  • None AHT
📍

Where

1 site
Oscar Lambret Center
Lille, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy